Trump Announces Historic Prescription Drug Price Cuts Ahead Of Midterms

President Donald Trump is positioning a major crackdown on inflated prescription drug costs as a defining issue ahead of the midterm elections — framing the effort as both an economic and moral correction long overdue in American health care. The president described the change as a “shock to the system” that will bring immediate relief to millions of Americans struggling under soaring pharmaceutical prices.

This week, Trump announced a landmark agreement with Pfizer that will allow state Medicaid programs to purchase the company’s medications at most-favored-nation (MFN) pricing — meaning states will now pay the lowest price available among developed countries, rather than the artificially inflated rates typically charged in the United States.

A White House fact sheet highlighted some of the most dramatic examples:

• Eucrisa, a dermatitis treatment, will drop by 80%.
• Xeljanz, used for rheumatoid arthritis, will fall by 40%.
• Zavzpret, a migraine medication, will see a 50% reduction.

Trump emphasized that these price cuts are not a one-off gesture, but the opening move in a broader restructuring of the pharmaceutical market.

“We’re going to have another meeting next week on this,” Trump told reporters. “We have another great company coming in, similar kind of numbers, but we’re going to show you some 1,000 percent drops in prices. There has never been anything like this in the history of medicine.”

Speaking with Breitbart News, the president made clear the political implications as the midterms approach.

“Huge,” he said. “I’ve wanted to do it from the beginning, from my first day and first term, and we were doing so well. We had the greatest economy we’ve ever had. Everything was good, and then we’re ready to do this, which is complex and big. It’s a big change. But what happened is COVID came, and we focused on COVID.”

Trump pointed to his emergency mobilization during the pandemic — including breakthrough therapies and historic cooperation with pharmaceutical leadership — as proof that Washington can act swiftly when driven by strong leadership.

“We focused on COVID very hard with Albert, with the other companies, with everybody,” Trump said. “Regeneron was a great thing. We did a lot of therapeutics that were fantastic, and so we focused on that.”

Now, back in the White House, the president said lowering prescription costs has been a top priority for eight months and is central to restoring fairness for American consumers.

“This is a very big deal,” Trump said. “This is a big shock to the system. The world is going to go up a little bit. We’re going to come down a lot. But now it’s fair. We’re going to be paying the same thing.”

For decades, Americans have effectively subsidized other nations’ lower drug prices — something Trump has repeatedly denounced as “global freeloading.” The MFN policy cuts straight to the heart of that imbalance, ensuring U.S. citizens no longer pay more simply because they are American.

Health officials praised the agreement, while analysts noted that pharmaceutical companies have historically resisted such pricing reforms. But Trump dismissed concerns that innovation would be harmed.

“Companies are going to continue to make plenty of money,” Trump said. “But Americans are not going to be ripped off anymore. Those days are over.”

And the timing could not be more favorable to the president: support among likely voters is rising sharply. The latest Rasmussen Reports daily tracking poll shows 53% approval, representing a 10-point net swing in just days. The shift coincides with Trump’s recent high-profile diplomatic visit to South Korea — a reminder of his continued stature on the world stage.

With prices coming down and pocketbooks getting relief, Trump said the impact will be felt not only at the pharmacy counter — but at the ballot box.

“This is not just policy,” he said. “This is people’s lives. This is fairness. And it’s happening right now.”